Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Mar Drugs ; 17(11)2019 Nov 04.
Artigo em Inglês | MEDLINE | ID: mdl-31690015

RESUMO

This study aimed to investigate the effect of astaxanthin (ASX) extracted and ASX powder from shrimp (Litopenaeus vannamei) shells on Wistar rats with Alzheimer's disease, induced by amyloid-ß (1-42) peptides. In this task, the rats were divided into eight groups: (1) Control, (2) sham operate, (3) negative control (vehicle) + Aß1-42, (4) ASX extract+Aß1-42, (5) commercial ASX + Aß1-42, (6) ASX powder + Aß1-42, (7) blank powder + Aß1-42, and (8) vitamin E + Aß1-42. All treatments were orally administrated for 30 days. At 14- and 29-days post injection, animals were observed in behavioral tests. On the 31st day, animals were sacrificed; the hippocampus and cortex were collected. Those two brain areas were then homogenized and stored for biochemical and histological analysis. The results showed that the Aß1-42 infused group significantly reduced cognitive ability and increased memory loss, as assessed by the Morris water maze test, novel object recognition test, and novel object location test. Moreover, the Aß1-42 infused group exhibited a deterioration of oxidative markers, including glutathione peroxidase enzymes (GPx), lipid peroxidation (MDA), products of protein oxidation, and superoxide anion in the cortex and the hippocampus. Meanwhile, ASX powder (10 mg/kg body weight) showed a significant reduction in cognitive and memory impairments and oxidative stress which is greater than ASX extract in the same dose of compound or vitamin E (100 mg/kg body weight). Our study indicates the beneficial properties of ASX in alleviation of cognitive functions and reducing neurodegeneration in Wistar rats induced by amyloid-ß (1-42) peptides.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Disfunção Cognitiva/tratamento farmacológico , Estresse Oxidativo/efeitos dos fármacos , Administração Oral , Doença de Alzheimer/fisiopatologia , Peptídeos beta-Amiloides/metabolismo , Exoesqueleto/química , Animais , Modelos Animais de Doenças , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Aprendizagem em Labirinto , Transtornos da Memória/tratamento farmacológico , Penaeidae/química , Ratos , Ratos Wistar , Vitamina E/administração & dosagem , Vitamina E/farmacologia , Xantofilas/administração & dosagem , Xantofilas/isolamento & purificação , Xantofilas/farmacologia
2.
Food Sci Biotechnol ; 28(2): 529-537, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30956865

RESUMO

This study aimed to investigate the effects of phospholipid composition on the properties and bioavailability of astaxanthin-loaded liposomes using cell culture. Two mixtures of phospholipids with different proportions of phosphatidylcholine (PC, 23% and 70%) were used at various concentrations (0.8, 1.6, and 2.0% w/v) to prepare astaxanthin-loaded liposomes, which were investigated for entrapment efficiency (EE), antioxidant activity, morphology and changes in astaxanthin properties during a storage period of 8 weeks at 4 °C. Furthermore, Caco-2 human colon adenocarcinoma cells were employed to examine the cellular uptake of astaxanthin-loaded liposomes. The highest EE was observed with astaxanthin-loaded liposomes containing 70% PC, and used at the concentration of 2.0% w/v. Liposomes maintained the antioxidant activity of astaxanthin. All liposomal preparations were non-toxic. Cellular uptake of astaxanthin-loaded liposomes containing 70% PC was significantly higher than that of 23% PC-containing liposomes (p < 0.05).

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA